Urticaria, commonly known as hives, is a skin condition characterized by raised, itchy welts that can appear suddenly and vary in size and location. In some cases, it is accompanied by deeper swelling known as angioedema, often affecting areas such as the lips, eyelids, and hands.
While acute urticaria may resolve within days or weeks, chronic urticaria persists for six weeks or longer and can significantly impact daily life. The condition is often driven by immune system activity, though in many cases, the exact trigger remains unknown.
Symptoms can include intense itching, redness, swelling, and recurring flare-ups that may be unpredictable. Standard treatments such as antihistamines and immunomodulatory therapies may help control symptoms, but not all patients achieve complete or lasting relief.
Clinical trials are essential in advancing new treatment options for chronic urticaria. At Rejuvenation Dermatology, our studies focus on evaluating innovative therapies that target the underlying immune pathways responsible for the condition.
Participants receive access to investigational treatments in a structured, medically supervised environment. Each study follows strict ethical and regulatory standards, ensuring patient safety while contributing to the development of more effective and targeted therapies.
Our goal is to reduce the frequency and severity of flare-ups, control itching and swelling, and improve overall quality of life for individuals living with urticaria.
STUDY INFO:
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2).
If you are interested in joining this study, please click here.
STUDY INFO:
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, 12-WEEK PLACEBO-CONTROLLED STUDY WITH A 12-WEEK DOUBLE-BLIND EXTENSION PERIOD TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH CHRONIC SPONTANEOUS URTICARIA.
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2).
If you are interested in joining this study, please click here.
STUDY INFO:
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU).
If you are interested in joining this study, please click here.
EVIDENCE DRIVES BETTER URTICARIA CARE
We believe urticaria treatment should focus on long-term symptom control and improved quality of life. Our clinical trials are designed to evaluate advanced therapies that target immune-driven pathways responsible for chronic hives and swelling.
RESEARCH INTEGRATED INTO REAL CLINICAL PRACTICE
All studies are conducted within active dermatology clinics, ensuring patients receive care in a familiar and professional environment. Our dermatologists understand the unpredictable nature of urticaria and tailor care accordingly.
ETHICS ARE NON-NEGOTIABLE
Every urticaria trial undergoes independent ethics board review prior to enrollment. Participants are fully informed, carefully screened, and continuously monitored, with safety protocols that meet and exceed regulatory standards.
STANDARDIZED, NATIONAL EXECUTION
Our multi-site research network operates under centralized oversight and standardized protocols, ensuring consistent study execution, high-quality data collection, and reliable outcomes across all participating locations.
Clinical research at Rejuvenation Dermatology is driven by a commitment to advance patient care through evidence-based medicine. Through participating in regulated clinical trials, the organization helps to shape development of safer, more effective dermatologic treatments while ensuring patients receive care that meets the highest ethical and scientific standards.
Participation in clinical research enables Rejuvenation physicians to remain at the forefront of dermatologic innovation and provides patients with access to therapies that may not yet be commercially available.
DERMATOLOGY-LED RESEARCH
Our urticaria trials are led by experienced dermatologists with expertise in immune-mediated skin conditions. Physician oversight ensures every participant receives clinically sound, research-driven care.
FOCUS ON CHRONIC AND UNPREDICTABLE CASES
Chronic urticaria can be difficult to manage due to its unpredictable nature. Our studies are designed to address patients with persistent symptoms who may not respond to standard therapies.
SAFETY FIRST, ALWAYS
Patient safety is at the core of every study. Strict eligibility criteria, ongoing monitoring, and adherence to Good Clinical Practice guidelines ensure a safe and controlled research environment.
CONSISTENT EXECUTION, TRUSTED RESULTS
Sponsors rely on our ability to recruit efficiently and deliver high-quality, audit-ready data. This structured approach ensures a seamless and reliable experience for participants.
ADVANCING FUTURE URTICARIA TREATMENTS
Participation in clinical trials contributes to the development of new therapies that may significantly improve long-term outcomes for individuals living with chronic urticaria.
Yes, all studies follow strict medical and ethical guidelines.
Eligibility depends on the specific study but generally includes individuals with chronic or moderate to severe urticaria.
Urticaria, or hives, is a skin condition that causes raised, itchy welts on the skin.
Participants may access new therapies while receiving expert dermatological care.
URTICARIA CLINICAL TRIALS | CLINICAL TRIALS CANADA | REJUVENATION DERMATOLOGY
Rejuvenation Dermatology’s Clinical Trials Department is a national, multi-site research network dedicated to advancing dermatologic care through ethically conducted, regulated clinical research. Integrated within routine clinical practice, the department partners with global pharmaceutical sponsors to evaluate novel therapies and offers early access to innovative treatment options. The team supports industry-sponsored and investigator-initiated trials across a broad range of indications, collaborating closely with sponsors, CROs, investigators, and ethics boards to deliver high-quality data while maintaining a strong commitment to patient safety.
Since its inception, the division has evolved from a single research-focused clinic into a coordinated, multi-province research network. Today, it operates with standardized infrastructure, centralized oversight, and experienced investigators across Canada.
